Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial

被引:4
作者
Williams, Hannah [1 ]
Yuval, Jonathan B. [1 ,2 ]
Verheij, Floris S. [1 ]
Miranda, Joao [3 ]
Lin, Sabrina T. [4 ]
Omer, Dana M. [1 ]
Qin, Li-Xuan [4 ]
Gollub, Marc J. [3 ]
Kim, Tae-Hyung [3 ]
Garcia-Aguilar, Julio [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Colorectal Serv, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Tel Aviv Sourasky Med Ctr, Dept Surg, Tel Aviv, Israel
[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
关键词
TOTAL MESORECTAL EXCISION; OPEN-LABEL; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; TUMOR RESPONSE; CANCER; SURVIVAL; CHEMORADIATION; THERAPY;
D O I
10.1093/bjs/znae246
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Prospective randomized trials have not yet identified baseline features predictive of organ preservation in locally advanced rectal cancers treated with total neoadjuvant therapy and a selective watch-and-wait strategy.Methods This was a secondary analysis of the OPRA trial, which randomized patients with stage II-III rectal adenocarcinoma to receive either induction or consolidation total neoadjuvant therapy. Patients were recommended for total mesorectal excision, or watch and wait based on clinical response at 8 +/- 4 weeks after completing treatment. Standardized baseline clinical and radiological variables were collected prospectively. Survival outcomes, including total mesorectal excision-free survival, disease-free survival, and overall survival, were assessed by intention-to-treat analysis. Cox proportional hazards models were used to evaluate associations between baseline variables and survival outcomes.Results Of the 324 patients randomized for the OPRA trial, 38 (11.7%) had cT4 tumours, 230 (71.0%) cN-positive disease, 101 (32.5%) mesorectal fascia involvement, and 64 (19.8%) extramural venous invasion. Several baseline features were independently associated with recommendation for total mesorectal excision on multivariable analysis: nodal disease (HR 1.66, 95% c.i. 1.12 to 2.48), extramural venous invasion (HR 1.57, 1.07 to 2.29), mesorectal fascia involvement (HR 1.45, 1.01 to 2.09), and tumour length (HR 1.11, 1.00 to 1.22). Of these, nodal disease (HR 2.02, 1.15 to 3.53) and mesorectal fascia involvement (HR 2.02, 1.26 to 3.26) also predicted worse disease-free survival. Age (HR 1.03, 1.00 to 1.06) was associated with overall survival.Conclusion Baseline MRI features, including nodal disease, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict the likelihood of organ preservation after completion of total neoadjuvant therapy. Mesorectal fascia involvement and nodal disease are associated with disease-free survival. Prospective randomized studies have not yet evaluated baseline features that predict organ preservation in locally advanced rectal cancer treated with total neoadjuvant therapy and a selective watch-and-wait strategy. This secondary analysis of the OPRA trial demonstrated that baseline MRI features, including nodal status, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict total mesorectal excision-free survival. Nodal status and mesorectal fascia involvement are associated with disease-free survival.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Organ preservation for rectal cancer: What are the arguments in favor of radiotherapy?
    Larrouy, A.
    Giraud, N.
    Huguet, F.
    Vendrely, V.
    CANCER RADIOTHERAPIE, 2022, 26 (6-7): : 766 - 770
  • [22] Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation
    Mendiratta, Prateek
    Rini, Brian I.
    Tendulkar, Rahul D.
    UROLOGY, 2018, 113 : E1 - E2
  • [23] Organ preservation in rectal cancer, the desire of a new paradigm
    Dominguez Tristancho, Jose Luis
    CIRUGIA ESPANOLA, 2022, 100 (07): : 389 - 391
  • [24] Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials
    Ben Dhia, Syrine
    Chauviere, Damien
    Mitrea, Diana
    Schiappa, Renaud
    Loscos, Tanguy Pace
    Chamorey, Emmanuel
    Baron, David
    ACTA ONCOLOGICA, 2025, 64 : 120 - 128
  • [25] Organ preservation following short-course radiotherapy for rectal cancer
    Nilsson, Per J.
    Ahlberg, Madelene
    Kordnejad, Shahrzad
    Holm, Torbjorn
    Martling, Anna
    BJS OPEN, 2021, 5 (05):
  • [26] Organ preservation of the rectum-watch and wait
    Kim, Mia
    Germer, Christoph-Thomas
    COLOPROCTOLOGY, 2020, 42 (04) : 302 - 308
  • [27] Feasibility study of a Response Surveillance Program in locally advanced mid and low rectal cancer to increase organ preservation
    Boubaddi, Mehdi
    Fleming, Christina
    Vendrely, Veronique
    Frulio, Nora
    Salut, Cecile
    Rullier, Eric
    Denost, Quentin
    EJSO, 2023, 49 (01): : 237 - 243
  • [28] Feasibility of a tailored operative strategy from organ preservation to pelvic exenteration for cT4 rectal cancer depending on neoadjuvant response
    Fleming, Christina
    Harji, Deena
    Fernandez, Benjamin
    Francois, Marc-Olivier
    Assenat, Vincent
    Gilles, Pasticier
    Clement, Michiels
    Robert, Gregoire
    Denost, Quentin
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2024, 39 (01)
  • [29] Organ preservation in rectal cancer: current status and future perspectives
    Vande Putte, Dirk
    Van Nieuwenhove, Yves
    Willaert, Wouter
    Pattyn, Piet
    Ceelen, Wim
    COLORECTAL CANCER, 2015, 4 (04) : 185 - 197
  • [30] Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation
    Chen Wang
    Xiaoliang Liu
    Weiping Wang
    Zheng Miao
    Xiaoyan Li
    Dingchao Liu
    Ke Hu
    Current Treatment Options in Oncology, 2024, 25 : 434 - 452